Anaphylaxis to a Vedolizumab Infusion following Drug Holiday in a Patient with Ulcerative Colitis: A Case Report
Introduction: Vedolizumab is a commonly prescribed biologic agent due to its safety profile and clinical efficacy. Severe infusion-related reactions are exceedingly rare, with no previously documented cases of anaphylaxis to vedolizumab infusion following a drug holiday. Case Presentation...
Saved in:
| Main Authors: | Jadon Karp, Henry Shen, Thomas Goodwin, Miles P. Sparrow |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2025-02-01
|
| Series: | Case Reports in Gastroenterology |
| Online Access: | https://karger.com/article/doi/10.1159/000543387 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Combined eosinophilic gastroenteritis and ulcerative colitis successfully treated by vedolizumab: a case report
by: Hironobu Takedomi, et al.
Published: (2025-01-01) -
A systematic review of vedolizumab in treating pediatric ulcerative colitis: efficacy and safety insights
by: Khawla Abu Hammour, et al.
Published: (2025-07-01) -
Efficacy and Safety of Vedolizumab with Glucocorticoids vs Infliximabin Severe Ulcerative Colitis: A Retrospective Study
by: Zhang C, et al.
Published: (2025-06-01) -
Comparison of the Effectiveness of Vedolizumab and Ustekinumab in Patients with Ulcerative Colitis: A Real-World Retrospective Study
by: Kei Nomura, et al.
Published: (2024-09-01) -
Vedolizumab–steroid combination therapy improves long-term prognosis in patients with ulcerative colitis
by: Yosuke Yamada, et al.
Published: (2025-04-01)